Head to Head Survey: Spectral Diagnostics (OTCMKTS:EDTXF) & Adagio Medical (NASDAQ:ADGM)

Risk & Volatility

Spectral Diagnostics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Adagio Medical has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Profitability

This table compares Spectral Diagnostics and Adagio Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral Diagnostics	-832.89%	N/A	-361.73%
Adagio Medical	-12,465.28%	-248.26%	-125.31%

Earnings and Valuation

This table compares Spectral Diagnostics and Adagio Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral Diagnostics	$1.67 million	211.88	-$11.24 million	($0.07)	-17.69
Adagio Medical	$600,000.00	38.07	-$75.04 million	N/A	N/A

Spectral Diagnostics has higher revenue and earnings than Adagio Medical.

Insider and Institutional Ownership

48.1% of Adagio Medical shares are held by institutional investors. 1.5% of Spectral Diagnostics shares are held by company insiders. Comparatively, 53.5% of Adagio Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Spectral Diagnostics beats Adagio Medical on 6 of the 9 factors compared between the two stocks.

About Spectral Diagnostics

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.